Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TNF | P01375 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.42 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | LOX | P28300 | 1/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14406750 | 0.86 | ALDH1A1 (0.46) | ALDH1A1GAAHSD17B10DRD2NPC1 | |
| SCHEMBL8233359 | 0.83 | ALDH1A1 (0.47) | ALDH1A1GAAHSD17B10DRD2NPC1 | |
| SCHEMBL2378357 | 0.82 | ALDH1A1 (0.46) | ALDH1A1GAAHSD17B10DRD2NPC1 | |
| SCHEMBL7049486 | 0.82 | ALDH1A1 (0.46) | ALDH1A1GAAHSD17B10DRD2NPC1 | |
| SCHEMBL533931 | 0.82 | ALDH1A1 (0.46) | ALDH1A1GAAHSD17B10DRD2NPC1 | |
| SCHEMBL1127911 | 0.82 | HTR6 (0.51) | ALDH1A1GAAHSD17B10DRD2GRM2 | |
| SCHEMBL2542290 | 0.82 | ALDH1A1 (0.46) | ALDH1A1GAAHSD17B10DRD2NPC1 | |
| SCHEMBL4012816 | 0.82 | ALDH1A1 (0.46) | ALDH1A1GAAHSD17B10DRD2NPC1 | |
| SCHEMBL30661269 | 0.82 | DRD2 (0.48) | ALDH1A1GAAHSD17B10DRD2NPC1 | |
| SCHEMBL29411715 | 0.82 | ALDH1A1 (0.46) | ALDH1A1GAAHSD17B10DRD2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190010159-A1 | NOVEL KINASE INHIBITOR AGAINST WILD-TYPE AND MUTANT EGFR | PRECEDO PHARMACEUTICALS CO., LTD (CN) | 2019-01-10 | — | — | US | claimed |
| EP-3398950-A1 | NOVEL KINASE INHIBITOR AGAINST WILD-TYPE EGFR AND MUTATED EGFR | Precedo Pharmaceuticals Co., Ltd. (CN) | 2018-11-07 | — | — | EP | claimed |
| EP-3398950-B1 | NOVEL KINASE INHIBITOR AGAINST WILD-TYPE EGFR AND MUTATED EGFR | PRECEDO PHARMACEUTICALS CO LTD (CN) | 2021-08-11 | — | — | EP | disclosed |
| CN-106928231-B | Novel EGFR wild type and mutant kinase inhibitors | 合肥中科普瑞昇生物医药科技有限公司 | 2021-06-01 | — | — | CN | disclosed |
| US-10781214-B2 | Kinase inhibitor against wild-type and mutant EGFR | PRECEDO PHARMACEUTICALS CO., LTD. (CN) | 2020-09-22 | — | — | US | disclosed |
| US-20190010159-A1 | NOVEL KINASE INHIBITOR AGAINST WILD-TYPE AND MUTANT EGFR | PRECEDO PHARMACEUTICALS CO., LTD (CN) | 2019-01-10 | — | — | US | disclosed |
| EP-3398950-A1 | NOVEL KINASE INHIBITOR AGAINST WILD-TYPE EGFR AND MUTATED EGFR | Precedo Pharmaceuticals Co., Ltd. (CN) | 2018-11-07 | — | — | EP | disclosed |
| CN-1155600-C | 2, 3-diaryl pyrazolo [1, 5-b ] pyridazine derivatives, their preparation and their use as cyclooxygenase 2 inhibitors | — | 2004-06-30 | — | — | CN | disclosed |
| EP-0882715-B1 | NOVEL N-(UNSUBSTITUTED OR SUBSTITUTED)-4-SUBSTITUTED-6-(UNSUBSTITUTED OR SUBSTITUTED)PHENOXY-2-PYRIDINECARBOXAMIDES OR THIOCARBOXAMIDES, PROCESSES FOR PRODUCING THE SAME, AND HERBICIDES | KUREHA CHEMICAL IND CO LTD (JP) | 2003-04-23 | — | — | EP | disclosed |
| CN-1278263-A | 2,3-diaryl-pyrazolo [1,5-B] pyridazines derivatives, their prepn. and use as cyclooxygenase 2 (cox-2) inhibitors | GLAXO GROUP LTD (GB) | 2000-12-27 | — | — | CN | disclosed |
| EP-0882715-A1 | NOVEL N-(UNSUBSTITUTED OR SUBSTITUTED)-4-SUBSTITUTED-6-(UNSUBSTITUTED OR SUBSTITUTED)PHENOXY-2-PYRIDINECARBOXAMIDES OR THIOCARBOXAMIDES, PROCESSES FOR PRODUCING THE SAME, AND HERBICIDES | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190010159-A1 | NOVEL KINASE INHIBITOR AGAINST WILD-TYPE AND MUTANT EGFR | EGFR, ERBB2, ERBB3 | ALDH1A1 3127/4885GAA 2171/4885HSD17B10 2999/4885 |
| US-10781214-B2 | Kinase inhibitor against wild-type and mutant EGFR | EGFR, ERBB2, ERBB3 | ALDH1A1 3248/4885GAA 1664/4885HSD17B10 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.